金吾财讯 | 拜耳(BAYRY)与生物技术公司Iambic Therapeutics联合宣布，双方已达成一项全新的药物研发合作协议。拜耳将全面引入Iambic的前沿AI研发平台，共同聚焦于小分子药物的发现与优化，以期攻克此前被行业视为“不可成药”的疾病靶点，为拜耳的早期研发管线注入创新动力。此次双方深化AI跨界合作，旨在打破传统新药研发成本高昂、周期漫长等痛点。根据协议，拜耳将获得Iambic旗下顶尖的前沿AI模型Enchant和NeuralPLexer的使用权。这两项前沿技术专注于多模态终点预测，能够更精准地识别全新的药物切入点，大幅缩短分子结构优化所需的时间，并提高药物在临床前的筛选成功率，为拜耳未来十年的核心管线筑牢基础。同时，Iambic将获得一笔首付款，并在未来有权获得基于特定里程碑的开发款项及上市后的销售特许权使用费。面对跨国药企纷纷拥抱生成式AI的大趋势，拜耳此举再次表明，利用“分子超级智能”缩短研发时间、降低试错成本已成为生物医药行业竞速的新常态。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.